Market Place
Sourcing Support
AlloVir finds new identity via eye disease biotech merger
11 Nov 2024 //
FIERCE BIOTECH
AlloVir & Kalaris Announce Merger Focused on Retina Diseases
08 Nov 2024 //
GLOBENEWSWIRE
AlloVir lays off 95% of staffers after shuttering PhIII cell therapy trials
05 Jan 2024 //
ENDPTS
Reeling from triple phase 3 failure, AlloVir cuts 95% of staff
05 Jan 2024 //
FIERCE BIOTECH
AlloVir to wind down PhIII trials for futility
26 Dec 2023 //
ENDPTS
Triple phase 3 disaster sends AlloVir shares plunging 64%
21 Dec 2023 //
FIERCE BIOTECH
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
16 Nov 2023 //
BUSINESSWIRE
AlloVir Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
AlloVir to Present at Upcoming Investor Conferences
28 Aug 2023 //
BUSINESSWIRE
AlloVir Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
AlloVir Announces Proposed Public Offering of Common Stock
21 Jun 2023 //
BUSINESSWIRE
AlloVir Announces Pricing of Public Offering of Common Stock
21 Jun 2023 //
BUSINESSWIRE
AlloVir Presents Positive Final Results From A PII Trial Evaluating Posoleucel
05 Jun 2023 //
BUSINESSWIRE
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA,CCO
16 May 2023 //
BUSINESSWIRE
AlloVir Reports First Quarter 2023 Financial Results
04 May 2023 //
BUSINESSWIRE
AlloVir to Present at the BofA Securities 2023 Health Care Conference
01 May 2023 //
BUSINESSWIRE
AlloVir Announces Positive Results Including Long-Term Mortality Data in Ph 2
26 Apr 2023 //
BUSINESSWIRE
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
23 Feb 2023 //
BUSINESSWIRE
AlloVir`s cell therapy tackles virus in kidney transplant trial
16 Feb 2023 //
FIERCE BIOTECH
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
15 Feb 2023 //
BUSINESSWIRE
AlloVir Announces Final Results from Phase 2 Study of Posoleucel with BK Viremia
15 Feb 2023 //
BUSINESSWIRE
AlloVir to Participate in the SVB Securities Global Biopharma Conference
01 Feb 2023 //
BUSINESSWIRE
AlloVir Announces Plans to Complete Enrollment in Three PIII Posoleucel Studies
09 Jan 2023 //
BUSINESSWIRE
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
BUSINESSWIRE
AlloVir Announces Results in Phase 2 Posoleucel Multi-Virus Prevention Study
11 Dec 2022 //
BUSINESSWIRE
AlloVir Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
BUSINESSWIRE
Data from AlloVir’s PII Study of Posoleucel to be Highlighted in Presentation
03 Nov 2022 //
BUSINESSWIRE
AlloVir to Participate in the Morgan Stanley 20th Annual Global Conference
02 Sep 2022 //
PRESS RELEASE
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
31 Aug 2022 //
PRESS RELEASE
AlloVir Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
AlloVir Announces $126.6 Million Registered Direct Offering
27 Jul 2022 //
BUSINESSWIRE
AlloVir Reports PII Data Supporting the Ongoing Study of Posoleucel
07 Jun 2022 //
BUSINESSWIRE
FDA Grants RMAT Designation to AlloVir’s Posoleucel for Prevention of Infections
20 Apr 2022 //
BUSINESSWIRE
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel
22 Mar 2022 //
BUSINESSWIRE
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
10 Feb 2022 //
BUSINESSWIRE
FDA Grants RMAT Designation to AlloVir’s Posoleucel for Adenovirus Infections
05 Jan 2022 //
BUSINESSWIRE
Nektar Therapeutics Appoints Diana M. Brainard
15 Nov 2021 //
PRNEWSWIRE
FDA Grants ODD to AlloVir’s Posoleucel for the Hemorrhagic Cystitis
04 Oct 2021 //
BIOSPACE
FDA Grants ODD to AlloVir’s Posoleucel for the Hemorrhagic Cystitis
04 Oct 2021 //
BIOSPACE
AlloVir to Present at Morgan Stanley 19th Annual Global Healthcare Conference
07 Sep 2021 //
BUSINESSWIRE
AlloVir Reports Second Quarter 2021 Financial Results
06 Aug 2021 //
BUSINESSWIRE
AlloVir Reports Second Quarter 2021 Financial Results
06 Aug 2021 //
BUSINESSWIRE
Gilead`s virology lead Brainard jumps ship to AlloVir
24 Mar 2021 //
FIERCE BIOTECH
Gilead`s virology lead Brainard jumps ship to AlloVir
23 Mar 2021 //
FIERCEBIOTECH
AlloVir Announces FDA Clearance of Investigational NDA for ALVR106
17 Dec 2020 //
BIOSPACE
AlloVir Announces FDA Clearance of Investigational NDA for ALVR106
17 Dec 2020 //
BUSINESSWIRE
AlloVir Announces FDA Clearance of Investigational NDA for ALVR106
17 Dec 2020 //
BIOSPACE
Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data
07 Dec 2020 //
BUSINESSWIRE
AlloVir to Present at the Piper Sandler 32nd Virtual Healthcare Conference
24 Nov 2020 //
BUSINESSWIRE
AlloVir snags IND approval for T cell therapy; Sanofi and GSK 300m dose deal
18 Sep 2020 //
ENDPTS
AlloVir Announces the FDA Clearance of IND for ALVR109
17 Sep 2020 //
BIOSPACE
AlloVir Announces the FDA Clearance of IND for ALVR109 for COVID-19 Patients
17 Sep 2020 //
BIOSPACE
AlloVir Announces Closing of Upsized Initial Public Offering and Full Exercise
03 Aug 2020 //
GLOBENEWSWIRE
AlloVir raises $276M IPO to run broad cell therapy program
30 Jul 2020 //
FIERCEBIOTECH
Annexon, AlloVir gun for $100M IPOs
07 Jul 2020 //
FIERCE BIOTECH
European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M
26 Mar 2020 //
BUSINESSWIRE
EMA grants PRIME designation to AlloVir`s allogeneic, off-the-shelf
13 Feb 2020 //
PHARMABIZ
AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M
12 Feb 2020 //
PRESS RELEASE
Biotech builder ElevateBio reveals its first portfolio company: AlloVir
23 May 2019 //
FIERCE BIOTECH
